Imexpharm Pharmaceutical Joint Stock Company (IMEXPHARM) has explained fluctuation over 5% of revenue and profit in quarter 4/2009 with quarter 3/2009 as follow:

* Net revenue increased VND38.91 billion (25%) and gross profit increased VND23.27 billion (23%) because the company speeded up sales activities in the end of year at hospitals, clinics, etc.

* Financial expenses decreased VND2.7 billion because the provisions for long-term & short-term securities devaluation were deducted in advance. Financial incomes increased VND5.02 billion because of recording interests of fixed deposit.

* General and administrative expenses decreased VND6.3 billion because the provision for bad receivables was deducted in advance for VND3.5 billion of overdue debts over 03 months and the company also deducted for VND3.58 billion of goodwill in quarter 3/2009.

* Selling expenses increased VND30.29 billion because the company operated a product launching and paid whole additional selling expenses in 2009.

* Expenses of deferred corporate income tax arose VND1.88 billion. The company deducted the expenses in advance in December 2009 and will pay the expenses in quarter 1/2010.

The above reasons made profit after tax in quarter 4/2009 increase VND4.29 billion (29%) higher than that in quarter 3/2009.